Literature DB >> 19487666

Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer.

Jenny Chia1, Kim Pin Yeo, James C Whisstock, Michelle A Dunstone, Joseph A Trapani, Ilia Voskoboinik.   

Abstract

The pore-forming protein perforin is critical for defense against many human pathogens and for preventing a catastrophic collapse of immune homeostasis, manifested in infancy as Type 2 familial hemophagocytic lymphohistiocytosis (FHL). However, no evidence has yet linked defective perforin cytotoxicity with cancer susceptibility in humans. Here, we examined perforin function in every patient reported in the literature who lived to at least 10 years of age without developing FHL despite inheriting mutations in both of their perforin (PRF1) alleles. Our analysis showed that almost 50% of these patients developed at least 1 hematological malignancy in childhood or adolescence. The broad range of pathologies argued strongly against a common environmental or viral cause for the extraordinary cancer incidence. Functionally, what distinguished these patients was their inheritance of PRF1 alleles encoding temperature-sensitive missense mutations. By contrast, truly null missense mutations with no rescue at the permissive temperature were associated with the more common severe presentation with FHL in early infancy. Our study provides the first mechanistic evidence for a link between defective perforin-mediated cytotoxicity and cancer susceptibility in humans and establishes the paradigm that temperature sensitivity of perforin function is a predictor of FHL severity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487666      PMCID: PMC2701033          DOI: 10.1073/pnas.0903815106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  An adaptable standard for protein export from the endoplasmic reticulum.

Authors:  R Luke Wiseman; Evan T Powers; Joel N Buxbaum; Jeffery W Kelly; William E Balch
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

2.  Structure of C8alpha-MACPF reveals mechanism of membrane attack in complement immune defense.

Authors:  Michael A Hadders; Dennis X Beringer; Piet Gros
Journal:  Science       Date:  2007-09-14       Impact factor: 47.728

3.  Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function.

Authors:  Ilia Voskoboinik; Vivien R Sutton; Annette Ciccone; Colin M House; Jenny Chia; Phillip K Darcy; Hideo Yagita; Joseph A Trapani
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

4.  Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma.

Authors:  Sonia Cannella; Alessandra Santoro; Giuseppa Bruno; Marta Pillon; Lara Mussolin; Giovanna Mangili; Angelo Rosolen; Maurizio Aricò
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

5.  A teenage boy with late onset hemophagocytic lymphohistiocytosis with predominant neurologic disease and perforin deficiency.

Authors:  Andrew D Beaty; Christin Weller; Beth Levy; Carole Vogler; William S Ferguson; Alma Bicknese; Alan P Knutsen
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

7.  Crystal structure of the MACPF domain of human complement protein C8 alpha in complex with the C8 gamma subunit.

Authors:  Daniel J Slade; Leslie L Lovelace; Maksymilian Chruszcz; Wladek Minor; Lukasz Lebioda; James M Sodetz
Journal:  J Mol Biol       Date:  2008-04-03       Impact factor: 5.469

Review 8.  The adaptive immune response to sporadic cancer.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

9.  Chemical and biological approaches synergize to ameliorate protein-folding diseases.

Authors:  Ting-Wei Mu; Derrick Sek Tong Ong; Ya-Juan Wang; William E Balch; John R Yates; Laura Segatori; Jeffery W Kelly
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

10.  The molecular basis for perforin oligomerization and transmembrane pore assembly.

Authors:  Katherine Baran; Michelle Dunstone; Jenny Chia; Annette Ciccone; Kylie A Browne; Christopher J P Clarke; Natalya Lukoyanova; Helen Saibil; James C Whisstock; Ilia Voskoboinik; Joseph A Trapani
Journal:  Immunity       Date:  2009-05-14       Impact factor: 31.745

View more
  41 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.

Authors:  Kai Lehmberg; Kim E Nichols; Jan-Inge Henter; Michael Girschikofsky; Tatiana Greenwood; Michael Jordan; Ashish Kumar; Milen Minkov; Paul La Rosée; Sheila Weitzman
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

3.  Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect.

Authors:  Julien Carvelli; Christelle Piperoglou; Catherine Farnarier; Frédéric Vely; Karin Mazodier; Sandra Audonnet; Patrick Nitschke; Christine Bole-Feysot; Mohamed Boucekine; Audrey Cambon; Mohamed Hamidou; Jean-Robert Harle; Geneviève de Saint Basile; Gilles Kaplanski
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

Review 4.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

5.  Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients.

Authors:  Omer An; Attila Gursoy; Aytemiz Gurgey; Ozlem Keskin
Journal:  Protein Sci       Date:  2013-06       Impact factor: 6.725

6.  Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms.

Authors:  Christian S Backes; Kim S Friedmann; Sebastian Mang; Arne Knörck; Markus Hoth; Carsten Kummerow
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

7.  Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Authors:  Matthew B Dong; Guangchuan Wang; Ryan D Chow; Lupeng Ye; Lvyun Zhu; Xiaoyun Dai; Jonathan J Park; Hyunu R Kim; Youssef Errami; Christopher D Guzman; Xiaoyu Zhou; Krista Y Chen; Paul A Renauer; Yaying Du; Johanna Shen; Stanley Z Lam; Jingjia J Zhou; Donald R Lannin; Roy S Herbst; Sidi Chen
Journal:  Cell       Date:  2019-08-22       Impact factor: 41.582

Review 8.  Granzyme M: behind enemy lines.

Authors:  S A H de Poot; N Bovenschen
Journal:  Cell Death Differ       Date:  2014-01-10       Impact factor: 15.828

Review 9.  Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

Authors:  Adam J Adler; Payal Mittal; Joseph M Ryan; Beiyan Zhou; Jeffrey S Wasser; Anthony T Vella
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

10.  Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition.

Authors:  Mohammed S Chaudhry; Kimberly C Gilmour; Imran G House; Mark Layton; Nicki Panoskaltsis; Mamta Sohal; Joseph A Trapani; Ilia Voskoboinik
Journal:  Oncoimmunology       Date:  2016-06-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.